Curis, Inc. (CRIS)
Largest Insider Buys in Sector
CRIS Stock Price History Chart
CRIS Stock Performance
About Curis, Inc.
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, …
Insider Activity of Curis, Inc.
Over the last 12 months, insiders at Curis, Inc. have bought $0 and sold $0 worth of Curis, Inc. stock.
On average, over the past 5 years, insiders at Curis, Inc. have bought $0 and sold $28,729 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 25,000 shares for transaction amount of $24,500 was made by Rubin Marc (director) on 2017‑11‑16.
List of Insider Buy and Sell Transactions, Curis, Inc.
| 2022-01-31 | Sale | President & CEO | 3,094 0.0032% | $3.07 | $9,499 | -70.22% | ||
| 2022-01-27 | Sale | President & CEO | 2,406 0.0027% | $3.18 | $7,651 | -68.40% | ||
| 2021-01-26 | Sale | President & CEO | 3,094 0.0036% | $10.59 | $32,758 | -21.62% | ||
| 2021-01-25 | Sale | President & CEO | 2,283 0.0027% | $10.96 | $25,022 | -23.56% | ||
| 2020-01-24 | Sale | President & CEO | 3,094 0.0087% | $1.64 | $5,076 | -29.41% | ||
| 2020-01-23 | Sale | President & CEO | 3,658 0.0109% | $1.69 | $6,182 | -27.27% | ||
| 2019-01-24 | Sale | President & CEO | 3,094 0.0082% | $1.16 | $3,577 | +36.36% | ||
| 2019-01-23 | Sale | President & CEO | 2,397 0.0074% | $1.09 | $2,613 | +68.22% | ||
| 2019-01-23 | Sale | director | 18,500 0.0549% | $1.05 | $19,477 | +68.22% | ||
| 2019-01-23 | Sale | director | 14,800 0.0439% | $1.05 | $15,587 | +68.22% | ||
| 2019-01-23 | Sale | director | 18,500 0.0549% | $1.05 | $19,475 | +68.22% | ||
| 2019-01-23 | Sale | Head of Research & Development | 5,500 0.0166% | $1.07 | $5,900 | +68.22% | ||
| 2019-01-23 | Sale | director | 14,800 0.0439% | $1.05 | $15,581 | +68.22% | ||
| 2017-11-16 | director | 25,000 0.0176% | $0.98 | $24,500 | -46.99% | |||
| 2017-11-15 | President & CEO | 50,000 0.036% | $1.06 | $53,000 | -49.80% | |||
| 2017-05-05 | Sale | director | 16,176 0.0113% | $1.90 | $30,721 | -20.63% | ||
| 2017-05-04 | Sale | director | 30,100 0.0213% | $1.97 | $59,159 | -22.42% | ||
| 2017-05-03 | Sale | director | 30,000 0.0213% | $2.18 | $65,544 | -29.21% | ||
| 2017-05-02 | Sale | director | 35,646 0.0249% | $2.31 | $82,314 | -33.48% | ||
| 2017-05-01 | Sale | director | 38,113 0.0266% | $2.38 | $90,709 | -34.81% |
Insider Historical Profitability
| Aurigene Discovery Technologies Ltd | 10 percent owner | 27328464 322.7659% | $3.26 | 1 | 0 | +38.59% |
| PASSERI DANIEL R | director | 198898 2.3491% | $3.26 | 2 | 31 | <0.0001% |
| Fattaey Ali Ph.D. | President & CEO | 115890 1.3687% | $3.26 | 3 | 0 | <0.0001% |
| GRAY MICHAEL | CFO | 107304 1.2673% | $3.26 | 1 | 6 | <0.0001% |
| MCNAB JAMES R | director | 50000 0.5905% | $3.26 | 9 | 29 | +15.48% |
Institutional Investor Ownership
| Maverick Capital Ltd | $6.33M | 9.88 | 582,273 | 0% | +$0 | 0.12 | |
| M28 Capital Management Lp | $4.59M | 7.16 | 421,951 | 0% | +$0 | 3.39 | |
| Kingdon Capital Management | $3.09M | 4.82 | 284,150 | 0% | +$0 | 0.41 | |
| The Vanguard Group | $2.38M | 3.71 | 218,573 | +4.84% | +$109,754.41 | <0.0001 | |
| Cm Management Llc | $1.3M | 2.04 | 120,000 | +380% | +$1.03M | 0.03 |